title: Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule.
abstract: With the issuance of this final rule, the Deputy Administrator of the Drug Enforcement Administration (DEA) places the substance [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (suvorexant), including its salts, isomers, and salts of isomers, into schedule IV of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule IV controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities, or possess), or propose to handle suvorexant.
mesh_terms: D001381:Azepines / Q000145:classification*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000145:classification*; D000068796:Orexin Receptor Antagonists; D014230:Triazoles / Q000145:classification*; D014481:United States
chemical_list: D001381:Azepines; D006993:Hypnotics and Sedatives; D000068796:Orexin Receptor Antagonists; D014230:Triazoles